COVID-19 vaccine: RDIF, Hetero agree to produce Sputnik V in India
Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start production of Sputnik V in India at the beginning of 2021
- Nov 27, 2020,
- Updated Nov 27, 2020 11:58 AM IST
Russia's sovereign wealth fund and Indian pharmaceutical company Hetero have agreed to produce over 100 million doses per year in India of the Sputnik V vaccine against COVID-19, according to a statement on the Sputnik V Twitter account on Friday.
Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start production of Sputnik V in India at the beginning of 2021, the statement said.
Phase II-III trials are ongoing in India, the statement said. Drugmaker Dr Reddy's Laboratories Ltd has said it expects late-stage trials to be completed by as early as March 2021.
Also read: 'India, top priority': Serum Institute CEO Adar Poonawalla on COVID-19 vaccine distribution plan
Also read: COVID-19 vaccine: $4.3 billion urgently needed for COVAX scheme, says WHO
Russia's sovereign wealth fund and Indian pharmaceutical company Hetero have agreed to produce over 100 million doses per year in India of the Sputnik V vaccine against COVID-19, according to a statement on the Sputnik V Twitter account on Friday.
Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start production of Sputnik V in India at the beginning of 2021, the statement said.
Phase II-III trials are ongoing in India, the statement said. Drugmaker Dr Reddy's Laboratories Ltd has said it expects late-stage trials to be completed by as early as March 2021.
Also read: 'India, top priority': Serum Institute CEO Adar Poonawalla on COVID-19 vaccine distribution plan
Also read: COVID-19 vaccine: $4.3 billion urgently needed for COVAX scheme, says WHO